MetaCap

Zoetis Inc. Class A (ZTS)

NYSE: ZTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

79.11-1.68 (-2.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ZTS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$32.14B
Dividend yield
2.64% ($2.09)
Ex-dividend date
Oct 30, 2026
52-week range
68.77 – 132.49
Day range
78.80 – 83.08
Volume / Avg
6.10M / 4.51M
Beta
—

52-week range

$68.77$132.49

ZTS stock today

On Nov 20, ZTS ended the session at $79.11, shedding $1.68 (2.08%), versus the S&P 500's 3.70% decline. Shares are 40.3% below their 52-week high of $132.49, set on Feb 12, 2026 and 15.0% above the 52-week low of $68.77, near the bottom of the past year's range. ZTS is down 37.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.2%.

At 13.5x trailing earnings, Zoetis trades below the peer-group median of 43.2x. Its forward P/E of 12.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Zoetis pays an annual dividend of $2.09 per share, a 2.64% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Zoetis

Company profile

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Kristin C. Peck
Headquarters
Parsippany, NJ
Employees
14,500
IPO year
2013
Website
zoetis.com

Financial highlights

Full financials

In fiscal 2025, Zoetis generated $9.47 billion in revenue, up 2.3% from fiscal 2024, its 10th consecutive year of revenue growth. Net income was $2.67 billion (+7.5% year over year), for a net margin of 28.2% versus a median of 26.2% in the prior 5 years. Gross margin was 71.8% (up from 70.6%).

Zoetis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$9.47B$9.26B$8.54B$8.08B$7.78B
Growth+2.28%+8.33%+5.74%+3.91%+16.49%
Net income$2.67B$2.49B$2.34B$2.11B$2.04B
EPS (diluted)$6.02$5.47$5.07$4.49$4.27

Analyst forecast

Forecast

Consensus (16 analysts)

buy

Avg. price target

$89.69+13.37%

  • Strong buy 4
  • Buy 2
  • Hold 10
  • Sell 0
  • Strong sell 0

Target range

Low $73.00High $115.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$1.44 vs $1.51
Surprise
-4.64%

Dividends

Dividend history
Annual dividend
$2.09
Last payment
$0.53
Ex-dividend date
Oct 30, 2026

ZTS news

All ZTS news

Zoetis peers

Health Care sector
ZTS peer companies
CompanyPrice% ChgMarket capCompare
GMABGenmab A/S ADS50.60-1.46%$31.20Bvs ZTS
INSMInsmed Incorporated141.33-2.17%$31.01Bvs ZTS
ROIVRoivant Sciences Ltd.38.66-0.78%$28.01Bvs ZTS
RPRXRoyalty Pharma plc Class A68.45+1.08%$39.36Bvs ZTS
UTHRUnited Therapeutics Corporation554.73-0.78%$23.63Bvs ZTS
VTRSViatris Inc.19.63-1.26%$22.50Bvs ZTS
ONCBeOne Medicines Ltd. ADR390.94-2.19%$44.66Bvs ZTS
ALNYAlnylam Pharmaceuticals Inc.143.82-2.71%$19.26Bvs ZTS

Indexes, lists and sector

Zoetis stock FAQ

What is Zoetis's stock price today?

ZTS last traded at $79.11 as of Nov 20, 4:00 PM EST, down 2.08% on the day. Prices are delayed at least 15 minutes.

Does Zoetis pay a dividend?

Yes. Zoetis pays $2.09 per share annually, a 2.64% yield. The most recent dividend of $0.53 had an ex-dividend date of Oct 30, 2026.

What is ZTS's P/E ratio?

ZTS trades at a trailing P/E ratio of 13.45 and a forward P/E of 12.41, compared with a median of 43.2 for its closest peers.

Is Zoetis in the S&P 500?

Yes. Zoetis (ZTS) is a constituent of the S&P 500 index.

Who is Zoetis's CEO?

Ms. Kristin C. Peck is the chief executive officer of Zoetis Inc. Class A, which has about 14,500 employees.

What is the ZTS 52-week high?

The 52-week high for ZTS is $132.49 and the 52-week low is $68.77. The stock is currently 40.3% below its high.

Compare ZTS